(rolls pedestal into the room, climbs on top) (

(rolls pedestal into the room, climbs on top)

(cracks knuckles)

OK, here we go. Icon time.

"75% of the patients who exhibited a lower level of circulating cells after leronlimab (86%) or at baseline (14%) exhibited a 3600% increase in 12-month Overall Survival (“OS”) (p = 0.0004), as compared to a 980% increase in OS reported by the Company on August 25, 2021."

75% of patients saw a 3,600% increase in overall survival. That survival increase was regardless of if they saw lower circulating tumor cells or not. Apparently 86% of the group did see lowered CTCs while 14% at baseline did not see improvement in that marker.

(checks notes, rereads the press release)

(scratches head)

Actually, it may be that at baseline (of the 75% of patients showing this 3,600% increase in OS) there were 14% of the patients who already had low circulating tumor cells while 86% of the patients in the trial saw their baseline CTCs lower after taking Leronlimab. But regardless, 75% of all patients in the trial saw in increase of 3,600% in overall survival.

(looks again at the press release)

(meanders out of the room lost in thought)